HOME >> MEDICINE >> NEWS
Penn study shows how next-generation diabetic drugs could work more selectively

(Philadelphia, PA) In an attempt to find a new generation of diabetic drugs that will minimize side effects, researchers at the University of Pennsylvania School of Medicine report a new understanding of how thiazolidinediones (TZDs), widely used diabetic medications, work in fat cells. With yearly sales exceeding billions of dollars, TZDs such as rosiglitazone maleate (Avandia) and pioglitazone hydrochloride (Actos) help to maintain diabetics' blood-sugar levels.

In fat cells, TZDs turn on a small set of genes, which aren't normally turned on, by targeting the receptor PPAR. To tease out how the medications work specifically, the investigators set out to determine the difference between the genes that are ordinarily turned on in fat cells and the genes that are turned on only when diabetics are given the TZDs.

A new study from the laboratory of Mitchell Lazar, MD, PhD, Director of the Institute for Diabetes, Obesity, and Metabolism at Penn, has found that PPAR can turn genes both on and off. "What regulates it, in this case, is the drug, which is acting as a switch to turn genes on," says Lazar. "This paper shows that we can separate the two different aspects of the drug's action on fat cells." These findings appear in the January 28th online edition of Genes & Development and will appear in the February 15th print issue.

Knowing how to turn a gene off may permit researchers to develop drugs that would decrease TZD-related side effects such as weight gain and edema. Indeed, preclinical research is already underway to design drugs called SPPARMs, selective PPAR modulators, which would specifically target genes in fat cells that can turn off the molecular pathways that may lead to these serious side effects.

Working with mouse fat cells, Lazar's study suggests that one way to get gene-selective actions would be to target this ability to turn off genes without affecting the ability to turn others on. "Since these are separate pro
'"/>

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine
27-Jan-2005


Page: 1 2

Related medicine news :

1. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
2. UMaine study looks at infants and chronic nighttime crying
3. Chronic pain treatments more effective when taken together, new study shows
4. UNC study: Most N.C. family practitioners engage in unrecognized community service
5. New study in Nature demonstrates protection against cell death during heart attack
6. UCSF study offers insight into human circadian rhythms
7. International breast cancer prevention study launches in the United States and Canada
8. UW study shows blacks and Latinos are more satisfied with physicians of the same race
9. Physicians may not be accurate in their confidence levels of their diagnoses, says Pitt study
10. Advertising by academic medical centers may risk eroding public trust, says study
11. Fat may promote inflammation, new study suggests

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/11/2019)... ... November 11, 2019 , ... PracticeLink Live! Atlanta Physician Career ... event will begin at 5:00 p.m. and continue until 8:00 p.m. A free, optional ... Search, will begin at 6:30 p.m. , Both the career fair and seminar are ...
(Date:11/9/2019)... ... ... Mount Sinai Medical-Legal Partnership (MSMLP), an organization formed to address the legal needs ... and advocacy assistance to families and patients in need. The announcement was made at ... of Blaine (“Fin”) Fogg, who was a member of the Boards of Trustees of ...
(Date:11/7/2019)... (PRWEB) , ... November 06, 2019 , ... An October ... obesity in the United States. According to the article, while no U.S. state had ... population that is over 20 percent obese. The article cites quite a few reasons ...
(Date:11/7/2019)... ... 2019 , ... Understanding UDI in EU Device Regulations, An FDAnews Webinar, Thursday, ... EU device and IV diagnostics sales in jeopardy? , It’s not a trick question. ... and many device and diagnostics makers simply aren’t prepared. , Not yet anyway. , ...
(Date:11/6/2019)... ... November 06, 2019 , ... ... label nutritional bar and functional powder solutions, recently achieved FSSC 22000 Certification of ... “We are pleased to share the news that we have achieved FSSC 22000 ...
Breaking Medicine News(10 mins):
(Date:11/5/2019)... MONTCLAIR, N.J. (PRWEB) , ... November 05, 2019 ... ... San Antonio, 555 South Alamo Street in Texas will be a timely program ... instruction in the management of chronic pain. , The Texas Medical Board requires ...
(Date:11/5/2019)... ... November 05, 2019 , ... ... Nov. 13-14: How to Build a Sponsor Risk Management Program, Friday, Nov. ... Wednesday-Friday, Nov. 13-15, 2019 • Philadelphia, PA , https://www.fdanews.com/cwiche6gcp , ...
(Date:11/4/2019)... ... ... E-Z-C Pak Creator Dr. Sarath Malepati reeled in famed entrepreneur ... Shark Tank on ABC. EZC Pak is a physician formulated immune support pack composed ... use in colds and flu. , Dr. Malepati negotiated a $125,000 investment for a ...
Breaking Medicine Technology:
Cached News: